Progression Free Survival in Lung Cancer Adenocarcinoma Wild Type Patients with Pemetrexed Regimen Combination of Cisplatin compared to Carboplatin
DOI:
https://doi.org/10.11594/jk-risk.04.2.2Keywords:
PFS, wild type, cisplatin, carboplatin, pemetrexedAbstract
Background: Progression-free survival (PFS) is a parameter to measures the progression of wild type adenocarcinoma lung cancer. Literature studies have shown that the combination platinum based-pemetrexed chemotherapy is more effective to prolonged progressivity of wild type adenocarcinoma.
Aim: The aim of study to compared the PSF of wild type adenocarcinoma patients receiving cisplatin-pemetrexed and pemetrexed-carboplatin regimens at Dr. Saiful Anwar Hospital in 2018-2021.
Methods: A retrospective cohort study based on medical record of wild type adenocarcinoma patients.
Results: The results showed that the administration of a carboplatin-pemetrexed regimen has prolonged PFS (median 4 months, 95% CI 2.657-5.343) compared to the cisplatin-pemetrexed regimen (median 2 months, 95% CI 0.988-3.012). In addition, the risk of lung cancer progression based on PFS is not significantly influenced by the Karnofsky scale value of 70-80 (72.2%, HR 0.278). On the other hand, a history of smoking increases the risk of lung cancer progression, although it does not have a significant effect (HR 1,538).
Conclusion: Administration of the carboplatin-pemetrexed regimen prolongs PFS up to a range of 10-16 months, although there is no statistically significant difference compared to the cisplatin-pemetrexed.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.
Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Translational Lung Cancer Research. 2015;4(1):36–54.
Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M, Murad Mh. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Annals of Tho-racic Medicine. 2013;8(4):204.
Minnelli C, Laudadio E, Mobbili G, Galeazzi R. Con-formational insight on WT-and mutated-EGFR re-ceptor activation and inhibition by epigallocate-chin-3-gallate: Over a rational basis for the design of selective non-small-cell lung anticancer agents. International Journal of Molecular Sciences. 2020;21(5):1–17.
Karampeazis A, Voutsina A, Souglakos J, Ken-tepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated pa-tients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) ran-domized phase 3 study. Cancer. 2013 Aug 1;119(15):2754–64.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in sec-ond-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. The Lancet Oncology. 2012 Mar;13(3):300–8.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docet-axel as second-line treatment of patients with ad-vanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised con-trolled trial. The Lancet Oncology. 2013;14(10):981–8.
Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): A multicenter randomized trial. Annals of Oncology. 2014;25(12):2385–91.
Anwar J. Seri Buku Ajar Onkologi Toraks. Pen-gobatan Kanker Paru. I. Jakarta: PDPI; 2019. 7–24 p.
Xu T, Wu H, Jin S, Min H, Zhang Z, Shu Y, et al. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Medicine (United States). 2017;96(33):0–4.
Cheng YJ, Wu R, Cheng ML, Du J, Hu XW, Yu L, et al. Carboplatin-induced hematotoxicity among patients with nonsmall cell lung cancer: Analysis on clinical adverse events and drug-gene interac-tions. Oncotarget. 2017;8(19):32228–36.
Heist RS. First-Line Systemic Therapy for Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America. 2017;31(1):59–70.
USAMI E, KIMURA M, IWAI M, TAKENAKA S, TERAMACHI H, YOSHIMURA T. Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mo-lecular and Clinical Oncology. 2016 Apr;4(4):591–6.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for di-agnosis, treatment and follow-up. Annals of On-cology. 2018 Oct;29:iv192–237.
Sutandyo, N. Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. Acta medica Indonesiana. 2018;50:4.
Nicholsxon AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362–87.
Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, et al. EGFR mutation is associated with short pro-gression-free survival in patients with stage III non-squamous cell lung cancer treated with con-current chemoradiotherapy. Cancer Research and Treatment. 2019;51(2):493–501.
Setyawan UA, Pratiwi SD, Fitryanto A, Suwandi GS, Sari FI, Novelia Z. Profile Of Lung Cancer From East Java Tertiary Hospital: Clinicopathological Profile. Chest. 2019;155(4):202A.
Kementrian Kesehatan Republik Indonesia, Komite Penanggulangan Kanker Nasional, Na-sional K. Panduan Penatalaksanaan Kanker Paru. Jakarta; 2017.
Kimura T et al. Phase II study of carboplatin and pemetrexed in advanced EGFR-wild-type non-squamous non-small cell lung cancer: The central Japan lung study group trial 0906. Anticancer Research. 2016;36(4):1767–71.
Pangribowo S. Beban Kanker di Indonesia. Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI. 2019;1–16.
Tseng CH, Chiang CJ, Tseng J Sen, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Onco-target. 2017;8(58):98384–93.
Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gen-der in advanced lung adenocarcinoma. Oncotar-get. 2017 Nov 17;8(58):98384–93.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
